US4673565A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions containing hollow fine tubular drug delivery systems
Assignee: Bristol Myers Squibb Pharma Co
•
Filing: 1985-05-03
•
Granted: 1987-06-16
•
Expires: 2005-05-03
Abstract
Abstract Pharmaceutical compositions are provided which contain hollow fine tube drug delivery systems. The compositions comprise a pharmaceutically suitable carrier, preferably in the form of a capsule, tablet, suspension, or suppository, and at least one drug delivery system which consists essentially of (1) a polymeric tube having a membrane outer sheath and a hollow core, and (2) at least one drug compound contained within the core, said system contained in the composition in an amount sufficient to deliver a therapeutic amount of the drug contained therein at a predetermined rate over a predetermined period of time. By varying the polymer, the permeability of the outer sheath, the drug, the drug concentration in the hollow core of the tube, the tube diameter, the tube length, the tube core diameter, and the sealing of the tube ends, a wide variety of drug therapeutic amounts, rates and dosing times can be achieved.
Inventors
- 👤 Robert C. Di Luccio
- 👤 Ray B. Duggins
- 👤 Eli Shefter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:30
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0092; A61K9/70
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
92 words
A pharmaceutical composition comprising: a pharmaceutically suitable carrier and at least one drug delivery system consisting essentially of (1) a plurality of polymeric tubes having thin outer membrane sheaths and hollow cores, the length of each tube independently in the range of about 0.5 mm to about 5 cm, and (2) at least one solid, nonvaporizable drug compound contained within the cores, said system contained in the composition in an amount sufficient to deliver a therapeutic amount of the drug contained therein at a predetermined rate over a predetermined period of time.
Claim 2
Dependent Claim
92 words
A pharmaceutical composition comprising: a pharmaceutically suitable carrier and at least one drug delivery system consisting essentially of (1) a plurality of polymeric tubes having thin outer membrane sheaths and hollow cores, the length of each tube independently in the range of about 0.5 mm to about 5 cm, and (2) at least one solid, nonvaporizable drug compound contained within the cores, said system contained in the composition in an amount sufficient to deliver a therapeutic amount of the drug contained therein at a predetermined rate over a predetermined period of time.
Claim 3
Dependent Claim
18 words
The composition of claim 1 wherein the membrane outer sheath is impermeable and the tube ends are open.
Claim 4
Dependent Claim
14 words
The composition of claim 2 wherein the membrane outer sheath is permeable of semi-permeable.
Claim 5
Dependent Claim
18 words
The composition of claim 3 wherein 0 to 2 of the tube ends of each tube are sealed.
Claim 6
Dependent Claim
20 words
The composition of claim 1 wherein the core diameter is in the range of about 25%-90% of the outside diameter.
Claim 7
Dependent Claim
28 words
The composition of claim 1 wherein the drug compound concentration is in the range of about 1-90% by weight of the total weight of each tube and compound.
Claim 8
Dependent Claim
47 words
The composition of claim 5 wherein the concentration is in the range of about 5-75% by weight, and the length of each tube is independently in the range of less than 0.5 mm to about 6 mm, and whose aspect ratio is from about 1 to 30.
Claim 9
Dependent Claim
42 words
The composition of claim 5 wherein the membrane outer sheath of at least a portion of the tubes is permeable to water but not to the compound contained in the core, and these tubes have one end open and one end sealed.
Claim 10
Dependent Claim
20 words
The composition of claim 8 wherein the compound in the core is mixed with a pharmaceutically suitable salt or sugar.
Claim 11
Dependent Claim
14 words
The composition of claim 1 in the form of a capsule, tablet, or suppository.
Claim 12
Dependent Claim
48 words
The composition of claim 1 wherein the polymeric tube is formed from a polyolefin, a polyurethane, a copolymer of ethylene and vinyl acetate having at least 33% by weight vinyl acetate, a polyvinyl alcohol, or a blend of one of the aforesaid with a water-soluble polymer or salt.
Claim 13
Dependent Claim
27 words
The composition of claim 11 wherein the polymer is polypropylene having a melt index above 30 g/10 min and a solubility in hexadecylamine solvent above 20% w/w.
Claim 14
Dependent Claim
32 words
The composition system of claim 11 wherein the polymer is an ethylene-vinyl acetate copolymer having a melt index above 30 g/10 min and a solubility in a hydrocarbon solvent above 20% w/w.
Claim 15
Dependent Claim
33 words
The composition of claim 11 wherein the polymer is a segmented polyurethane/urea derived from polyether glycol soft segment containing no extra additives and soluble to greater than 30% w/w in dimethylacetamide or N-methylpyrrolidone.
Claim 16
Dependent Claim
42 words
The composition of claim 11 where the polymer is an ethylene-vinyl acetate copolymer blended with about 5 to 30% by weight of polyvinylpyrrolidone having a number average molecular weight of 15,000-40,000 or polyethylene glycol having a number average molecular weight of 400-20,000.
Claim 17
Dependent Claim
37 words
The composition of claim 14 wherein the polyurethane is a blend with about 5-50% by weight of polyvinylpyrrolidone having a number average molecular weight of 15,000-40,000 or polyethylene glycol having a number average molecular weight of 400-20,000.
References Cited (Backward Citations)
US4010308A
Cited
US3458616A
Cited
US3512183A
Cited
US3854480A
Cited
US4069307A
Cited
US3875300A
Cited
CA1052940A
Cited
US3991766A
Cited
US3944064A
Cited
US4055702A
Cited
US4001367A
Cited
US4031201A
Cited
US4012497A
Cited
US3946106A
Cited
US4017030A
Cited
US3946734A
Cited
US4076798A
Cited
US4144317A
Cited
US3994437A
Cited
US4113851A
Cited
US4122158A
Cited
US4203442A
Cited
US4175326A
Cited
US4224048A
Cited
US4312920A
Cited
GB2077586A
Cited
GB2077585A
Cited
US4525340A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-15 | 1990-12-15 | 1991-06-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-15 | 1994-12-15 | 1995-06-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-15 | 1998-12-15 | 1999-06-16 | $7700.00 | Window Closed / Lapsed |